Get access

Aripiprazole: A treatment for severe coprolalia in “refractory” Gilles de la Tourette syndrome

Authors

  • Mouna Ben Djebara MD,

    1. Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France
    2. INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris, France
    3. AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie, Paris, France
    4. Faculté de Médecine, Université Pierre et Marie Curie, Paris, France
    Search for more papers by this author
  • Yulia Worbe MD,

    1. Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France
    2. INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris, France
    3. AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie, Paris, France
    4. Faculté de Médecine, Université Pierre et Marie Curie, Paris, France
    Search for more papers by this author
  • Michael Schüpbach MD,

    1. Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France
    2. INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris, France
    3. AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie, Paris, France
    4. Faculté de Médecine, Université Pierre et Marie Curie, Paris, France
    Search for more papers by this author
  • Andreas Hartmann MD

    Corresponding author
    1. Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France
    2. INSERM, UMR 679, Neurology and Experimental Therapeutics, Paris, France
    3. AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie, Paris, France
    4. Faculté de Médecine, Université Pierre et Marie Curie, Paris, France
    • Centre d'Investigation Clinique, Pitié-Salpêtrière Group, 47, Boulevard de l′Hôpital, F-75651 Paris Cedex 13, France
    Search for more papers by this author

Abstract

Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics. © 2007 Movement Disorder Society

Ancillary